JACC Intervention Publishes MIV’s VESTASYNC I Trial Preliminary Results - Hydroxyapatite Non-Polymer-Based Sirolimus-Eluting Stent

MIV Therapeutics, Inc. (OTCBB: MIVI) (FRANKFURT: MIVN), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced that the Journal of the American College of Cardiology Intervention (JACC Intervention) published preliminary results from the VESTASYNC I trial.

More: continued here

Filed under: Medical Devices on October 27th, 2008